

RESEARCH

Open Access



Comparative genomics analysis and characterization of Shiga toxin-producing *Escherichia coli* O157:H7 strains reveal virulence genes, resistance genes, prophages and plasmids

Natalie Naidoo^{1*} and Oliver T. Zishiri¹

Abstract

Escherichia coli O157:H7 is a foodborne pathogen that has been linked to global disease outbreaks. These diseases include hemorrhagic colitis and hemolytic uremic syndrome. It is vital to know the features that make this strain pathogenic to understand the development of disease outbreaks. In the current study, a comparative genomic analysis was carried out to determine the presence of structural and functional features of O157:H7 strains obtained from 115 National Center for Biotechnology Information database. These strains of interest were analysed in the following programs: BLAST Ring Image Generator, PlasmidFinder, ResFinder, VirulenceFinder, IslandViewer 4 and PHASTER. Five strains (ECP19–198, ECP19–798, F7508, F8952, H2495) demonstrated a great homology with Sakai because of a few regions missing. Five resistant genes were identified, however, Macrolide-associated resistance gene *mdf(A)* was commonly found in all genomes. Majority of the strains (97%) were positive for 15 of the virulent genes (*espA*, *espB*, *espF*, *espJ*, *gad*, *chuA*, *eae*, *iss*, *nleA*, *nleB*, *nleC*, *ompT*, *tccP*, *terC* and *tir*). The plasmid analysis demonstrated that the IncF group was the most prevalent in the strains analysed. The prophage and genomic island analysis showed a distribution of bacteriophages and genomic islands respectively. The results indicated that structural and functional features of the many O157:H7 strains differ and may be a result of obtaining mobile genetic elements via horizontal gene transfer. Understanding the evolution of O157:H7 strains pathogenicity in terms of their structural and functional features will enable the development of detection and control of transmission strategies.

Keywords *Escherichia coli*, O157:H7, Plasmid, Resistant, Virulent, Genomic island, Prophage

Introduction

Shiga toxin-producing *Escherichia coli* (STEC) are foodborne pathogens that are a major health concern due to global disease outbreaks [1, 2]. STEC cause human gastrointestinal infections/diseases such as diarrhoea, hemorrhagic colitis and hemolytic uremic syndrome [3–6]. STEC is defined by virulence factors known as Shiga toxins [4, 7]. There are two types of Shiga toxin (Stx) (Stx1 and Stx2) that are encoded by *stx* genes that are produced in STEC [8–10]. These toxins are responsible for causing

*Correspondence:

Natalie Naidoo
211535425@stu.ukzn.ac.za

¹ School of Life Sciences, College of Agriculture, Engineering and Sciences, University of KwaZulu-Natal, Private Bag X54001, Durban 4000, South Africa



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

cytotoxicity in host cells [10, 11]. There are several Stx subtypes that differ in their biological activity including three subtypes for Stx1 (Stx1a, Stx1c, Stx1d) and seven subtypes for Stx2 (Stx2a to Stx2g) [12, 13]. STEC attain virulence genes through horizontal gene transfer from other pathogens [14]. Additionally, pathogenicity in STEC is also a result of the adherence factor intimin, which is encoded by the *eae* gene located in the Locus of Enterocyte Effacement (LEE) pathogenicity island [15]. LEE encodes a number of genes that play a role in the attaching and effacing [15].

Treatment for infections caused by STEC is limited, however, antibiotics can be used remove pathogens at the beginning stages of the infection [16–20]. STEC pathogens in hosts and varying environments are exposed to selective pressure leading to antibiotic resistance [21]. Research has shown that STEC are resistant to the following antibiotics in livestock and humans, tetracyclines, aminoglycosides, phenicols, streptomycin, erythromycin, carbapenems, cephalosporins, sulpha drugs and β -lactams [22–25]. Antibiotic resistance occurs via intrinsic (enzymatic degradation/ modification, efflux pumps, modification target sites or reduced cell wall permeability -) or acquired (horizontal gene transfer -) mechanisms or both [21, 26, 27]. Mobile genetic elements such as plasmid have demonstrated a role in the dissemination of antimicrobial resistance [28, 29]. Plasmids in STEC strains carry both virulent factors and antibiotic resistant (single and multiple) genes in highly conserved regions [30, 31].

Whole genome sequences available of STEC have shown high diversity because of horizontal gene transfer and genomic alterations [7, 32–37]. Using comparative genomics, identification of virulence and resistant genes and associated plasmids can be achieved to track pathogenic bacteria that pose as a public health threat. In the present study, the main aim was to compare whole genome sequences from all available *Escherichia coli* (*E. coli*) O157:H7 strains to investigate potential resistance, virulence and plasmid properties to distinguish between strains. Whole genome mapping for comparative genomics between the *E. coli* O157:H7 strains and the reference genome of pathogenic *E. coli*.

Results

BRIG

A comparative BLAST was performed using BRIG to determine homology between the reference strain (Sakai) and all other O157:H7 strains obtained. The greatest homology was observed between seven strains and Sakai: ECP19–198 (Fig. 1), ECP19–798 (Fig. 1), F7508 (Fig. 1), F8798 (Fig. 1), F8952 (Fig. 1), FRIK804 (Fig. 1) and H2495 (Fig. 1), because these strains had a few regions that

were missing, and these regions were short sections of nucleotides.

Resistance genes

There were 5 resistance genes identified according to the ResFinder (Fig. 2): Tetracycline resistance (*tet(B)*), Sulphonamide resistance (*sul2*), Aminoglycoside resistance (*aph(3'')-Ib*), Aminoglycoside resistance (*aph(6)-Id*), Macrolide-associated resistance gene (*mdf(A)*). In strain 2–6–2, BB24–1, FRIK944, FRIK2069, FRIK2455, FRIK2533 and SS TX 313–1 all 5 resistance genes were present. In strains, ECP17–1298, F6294 Show KS 470–1, TX 265–1 and Wll001 did not have any of the resistance genes present. All other strains only had the presence of the *mdf(A)* gene except the reference strain, with the exception of the NE1092-2 strain that also had resistance to the *aph(3'')-Ib* and *aph(6)-Id* genes.

In strain 2–6–2, BB24–1, FRIK944, FRIK2069, FRIK2455, FRIK2533 and SS TX 313–1 all 5 resistance genes were present. In strains, ECP17–1298, F6294 Show KS 470–1, TX 265–1 and Wll001 did not have any of the resistance genes present. All other strains only had the presence of the *mdf(A)* gene except the reference strain.

Plasmids

There were 13 plasmids identified according to Plasmid-Finder (Fig. 3): Col(MG828), Col156, Col8282, IncC, IncFIA, IncFIB, IncFII, IncFII(pCoo), IncII(pSFO), IncI-I(Alpha), IncI2(Delta), p0111 and pEC4115. FRIK2533 and TR01 had no plasmids. The reference strain only had plasmids for IncFIB and IncFII. Col(MG828) plasmid was only present in strain NE 1092–2. Col156 was only present in Z869. Col8282 was present in FRIK804. IncC was present in NE 1092–2, NE 1169–1 and NE1127. IncFIA is present in 2–6–2, 493/89, 2571, 7409, BB24–1, C1–057, EC4115, ECP19–2498, F1273, F6321, F6667, F7386, F8092B, F8492, F8797, FRIK944, FRIK2069, FRIK2455, JEONG-1266, LSU61, MB9–1, N8B7–2, Show KS 470–1, SS NE 1040–1, SS TX 313–1, SS TX 754–1, SS17, SS52, TB21–1, TW14359, TX 265–1, TX 376–2, Z1835 and Z1836. IncFIB was present in all strains except, F8492, FRIK2533, TR01 and Z1504. IncFII was present in all except 493/89, FRIK2533, LSU61, TR01 and Z1626. IncFII(pCoo) was only present in Z1834. IncII(pSFO) was present in 493/89 and LSU61. IncI-I(Alpha) was present in 3–5–1, ECP19–598, ECP19–2498 and G5295. IncI2(Delta) was present in E32511, F7386, H6437 and N8B7–2. p0111 present in F1273 and TX 376–2. pEC4115 present in EC4115, MB9–1, SS17, Z1832 and Z1833.

Virulence genes

There were 27 virulence genes identified/detected by VirulenceFinder (Fig. 4): *astA*, *cdtB*, *efa1*, *hra*, *iha*, *stx1A*,




Fig. 1 Comparison of Blast Ring Image Generated for *E. coli* O157:H7 strains




Fig. 2 The presence of resistance genes in *Escherichia coli* O157:H7 strains

stx1B, *stx2A*, *stxB*, *traT*, *espA*, *espB*, *espF*, *espJ*, *gad*, *chuA*, *eae*, *iss*, *nleA*, *nleB*, *nleC*, *ompT*, *tccP*, *terC*, *tir*, *stx1*, *stx2*. These virulence genes belong to categories such as, adherence, autotransporter, iron uptake, LEE-encoded TTSS effectors, non-LEE-encoded TTSS effectors, secretion system, and toxins. Virulence genes *espA*, *espB*, *espF*, *espJ*, *gad*, *chuA*, *eae*, *iss*, *nleA*, *nleB*, *nleC*, *ompT*, *tccP*, *terC*, *tir* were not present in EC4115, F3113 and TW14359 but present in all other strains. Other virulence genes that were more prevalent include: *astA* was present in all strains except EC4115, ECP19-198, F3113, F7508, F8952 and TW14359, *cdtB* was not present in all strains except 493/89, and MB41-1, *efa1* was not present in all strains except 493/89 and LSU61, *hra* was not present in all strains except 86-24 and ATCC 43888, *iha* was present in all strains except 493/89, EC4115, F3113 and TW14359, *traT* was present in all strains except 493/89, EC4115, F3113, LSU61 and TW14359. The *stx1A* was present in 38 strains and *stx1B* was present in 37 strains. The *stx2A* gene was absent in 9 strains and *stx2B* gene was absent in 12 strains. Majority of the strains did not have the *stx1* gene (only 38 strains had the gene) and the *stx2* gene was present in majority of the strains (only 9 strains did not have the gene).

Genomic islands

The chromosomal sequences of all strains were also analysed to detect genomic islands and the locations (Table 1). Based on this analysis the number of genomic islands present ranged from 74 to 120 islands. Virulence, pathogen associated, and resistance genes were also identified. No genomic islands were identified for the following 39 strains: ECP19-198, ECP19-598, ECP19-798,

ECP19-2498, TT12A, Z563, Z570, Z852, Z866, Z869, Z885, Z887, Z892, Z903, Z910, Z1486, Z1504, Z1615, Z1626, Z1723, Z1766, Z1767, Z1768, Z1769, Z1811, Z1812, Z1813, Z1814, Z1815, Z1816, Z1825, Z1826, Z1830, Z1831, Z1832, Z1833, Z1834, Z1835, Z1836. The number of virulence genes present ranged from 15 to 46. The number of pathogen associated genes ranged from 19 to 40. The number of resistant genes ranged present from 1 to 5. Strain F3113 had no resistant genes present.

PHASTER

Chromosomal sequences analysed by PHASTER identified phage-like elements in all 115 *E. coli* O157:H7 strains. The reference strain had 13 intact prophages, 5 questionable prophages, 4 incomplete prophages and 49.86% GC (guanine-cytosine content). The following data are significant results: Strains 1130, 2149, 2159, 4276, NE92 all had a total of 18 prophages (9 intact, 6 questionable and 3 incomplete) and percentage GC of 50.52%. Strains F7349, FWSEC004, NE 1169-1 and NE1127 had a total of 21 prophages (11 intact, 4 questionable and 6 incomplete) and percentage GC of 50.50%. Fourteen strains (Z852, Z903, Z1626, Z1766, Z1768, Z1769, Z1812, Z1815, Z1816, Z1825, Z1830, Z1831, Z1832 and Z1833) had 21 prophages (13 intact, 5 questionable and 3 incomplete) and percentage GC of 50.53%. The results for the PHASTER analysis are in Additional file 2.

Discussion

E. coli, specifically strain O157:H7 has become a well-known foodborne pathogen associated with human disease because of the genome constantly changing through mutation events and horizontal gene transfer [38-43] enables strains to diverge and adapt to colonize carrier




Fig. 3 The presence of plasmids in *Escherichia coli* O157:H7 strains

Table 1 The presence of genomic islands in *Escherichia coli* O157:H7 strains

Strain	No. of genomic islands
Sakai (reference strain)	110
2-6-2	117
3-5-1	109
17B6-2	113
86-24	91
493-89	85
611	101
1130	84
2149	83
2159	81
2571	103
3384	96
4276	80
7409	105
7636	97
8368	91
9234	89
ATTC 35150	99
ATCC 43888	95
ATCC 43890	91
BB24-1	102
C1-057	107
DEC4E	91
E32511	101
EC4115	106
ECP17-46	104
ECP17-1298	111
EDL933	106
F1273	105
F3113	97
F6294	110
F6321	102
F6667	105
F7349	102
F7386	112
F7508	115
F8092B	99
F8492	104
F8797	120
F8798	110
F8952	100
FESEC0004	94
FRIK804	113
FRIK944	115
FRIK2069	98
FRIK2455	101
FRIK2533	106

Table 1 (continued)

Strain	No. of genomic islands
G5295	107
Gim1-1	90
H2495	102
H6437	110
JEONG-1266	94
LSU61	96
MB9-1	98
MB41-1	97
N8B7-2	106
NE 1092-2	119
NE 1169-1	100
NE92	97
NE122	94
NE1127	103
OK1	99
PV15-279	109
Show KS 470-1	110
SS NE 1040-1	108
SS TX 313-1	113
SS TX 754-1	109
SS17	102
SS52	95
TB21-1	103
TR01	108
TT12B	95
TW14359	101
TX 265-1	108
TX 376-2	92
WII001	92
WII001	92

resistance (*aph(3'')-Ib*) and aminoglycoside resistance (*aph(6)-Id*) and 7 (6%) to tetracycline resistance (*tet(B)*), sulphonamide resistance (*sul2*). The key facilitator of the transport protein superfamily is the putative membrane protein (*mdfA*) which is coded by the *mdfA* gene and made up of 410 amino acid compounds [52]. Cationic and zwitterionic lipophilic compounds (benzalkonium, daunomycin, ethidium bromide, puromycin, rifampin, rhodamine, tetracycline and tetraphenylphosphonium) have a greater resistance to cells that express *mdfA* [52]. *mdfA* is also known to be resistant to vital antibiotics such as fluoroquinolones, erythromycin, chloramphenicol, and aminoglycosides [53]. From one hundred and fifteen *E. coli* O157:H7 strains evaluated, seven (6%) were resistant to all five antimicrobial resistant genes which suggests multi-drug resistant [54]. As a result, bacterial resistance increases against antibiotics

since resistance in bacteria is can be obtained through bacterial gene transfer [55]. Antibiotics are used in animals for growth promotion for food consumption, in human and veterinary medicine to treat and prevent infection and control spreading of the disease [56, 57]. Thus, the overuse and negligent use of antibiotics contributes to resistance.

Most plasmids are known to have an association with antimicrobial and/or virulence resistance [58]. Among the 13 plasmids identified, the IncF group of plasmids were more prevalent. IncF plasmids systems cause autonomous replication and code for addiction systems regularly based on toxin-antitoxin factors [59]. IncF plasmids most times encode for FII together with FIA and/or FIB [60]. IncFIB and IncFII represented majority of the strains, 97 and 96% respectively, IncFIA represented 30%, IncFII(pSFO) represented 0.017% and IncFII(pCoo) represented 0.008%. The IncF incompatibility family characterizes most plasmids that are associated with virulence in *E. coli* [61]. A study by Lambrecht and others in 2018 [62], showed that the FII-FIB combination was prevalent in commensal multi drug resistant *E. coli* in farm animals. Although IncF plasmids are well adapted in *E. coli*, these plasmids have a limited host range [63, 64]. Similarly, a comparative genomics study by Noll and others in 2018 showed that almost half their sample size (44%) identified IncF plasmids [65]. However, it is important to note that the pO157 plasmid is well studied in *E. coli* O157:H7 and other plasmids that are carried are not [66]. Previous studies have shown that IncF plasmids can combine many genes that cause resistance to antimicrobials such as, aminoglycosides, β -lactams, chloramphenicol, quinolones and tetracyclines [67, 68].

The current study identified multiple virulence genes in all the O157:H7 strains. Out of the 27 virulent genes identified, 15 virulence genes (*espA*, *espB*, *espF*, *espJ*, *gad*, *chuA*, *eae*, *iss*, *nleA*, *nleB*, *nleC*, *ompT*, *tccP*, *terC*, *tir*) was found dominating in majority of the O157:H7 strains (97%). These virulent genes belong to categories such as adherence, iron uptake, toxins, Shiga toxin, non-LEE and LEE-encoded TTSS effector and secretion system. *Tir* is a T3SS effector in STEC that plays a role as the receptor for the outer membrane protein intimin which facilitates interactions between the pathogen cell and host cell to get α -actinin to the pedestal for formation of attaching and effacing intestinal lesions [69]. The *tccP* gene codes for an effector protein that plays a direct role in EHEC infection [70]. Strains become extremely pathogenic when *tccP* gene is present together with *espJ*, *stx1a*, *stx2a* intimin and *tir* [71]. Intimin facilitates intimate attachment, this is encoded by the *eae* gene which enable attaching and effacing intestinal lesions between *E. coli* O157:H7 and host cell [72]. The above-mentioned

genes play an important role in making strains virulent [2] thus, the Sakai strain was used as a reference strain. *E. coli* O157:H7 strains either express *Stx1*, *Stx2*, or both genes, however the more toxic of the two genes is *Stx2* which causes hemorrhagic colitis and hemolytic uremic syndrome [2, 73, 74]. When isolates do not harbour the *stx* genes they are known as non-Shiga toxigenic *E. coli* O157:H7 [75]. A study by Iwu and others analysed O157:H7 strains from irrigation water and agricultural soil in two district municipalities in South Africa and showed that the overall prevalence of non-Shiga toxigenic *E. coli* O157:H7 was higher than STEC O157:H7 [75]. Non-Shiga toxigenic *E. coli* O157:H7 have been associated in severe diseases, however their influence as pathogens is not known [76].

The function of the genomic island of each strain is greatly dependent on the genetic makeup [77]. The genomic island results demonstrated varying number of GI. A study by Sharma and others in 2019 [48], identified 63 GI and 71 GI in the O157:H7 strains EDL933 and Sakai, respectively. However, in the present study, 106 GI and 110 GI in the O157:H7 strains EDL933 and Sakai, respectively. Genomic islands are known to display structural features that are similar, thus the difference in the number observed by Sharma and colleagues [48] and the present study could be a result of mobile elements being transferred by horizontal gene transfer [77, 78]. The genomic islands have the potential to contribute to the fitness, metabolic flexibility or increase the pathogenicity of the organisms [77]. The reference strain GI sequences can be aligned with GI sequence of interest to determine conserved GIs.

E. coli STEC strains are known to contain a high prophage content within the chromosome and sequences are highly variable among strains [79]. An approximation of 13–14% of the chromosome is made up of prophages in STEC O157:H7 [80, 81]. The number of predicted prophages varied greatly among the O157:H7 strains. The PHASTER analysis demonstrated the distribution of various bacteriophages. The results showed that there were three groups of strains that had the same prophages and GC percentage, suggesting that there is a high level of homology. To determine if these prophages are conserved phylogenetic and Basic Local Alignment Search Tool (BLAST) analysis can be done. In study by Weinroth and colleagues [82] demonstrated that all STEC O157:H7 showed great homology and shared three prophages. Bacteriophages that are that are similar suggest that they inhabit, adapt, and evolve from the same environment [83]. It is known that STEC genomes to possess prophages as well as integrative elements [84]. A study by in 2017 by Katani and colleagues [85] showed that prophages play an integral role in difference observed

between closely related strains. This study revealed that gaining and losing genomic mobile elements cause changes in strains, for example two strains SS17 and SS52 are closely related, however, SS17 possess the phage CP-9330 and SS52 does not [85]. Phages seem to play an important part in the diversity and evolutionary aspects of *E. coli* strains such as O157:H7, therefore it is speculated that specific traits or mechanisms such as fitness and adherence can be transferred from strain to host [85]. This speculation and should be tested further using additional comparative phage characterization [85]. The genome of JEONG-1266, EC4115, and SS17 contained a total of 19 prophage regions which were highly conserved demonstrating a close evolutionary relationship [79].

Conclusions

This study undertook a whole genome comparative analysis of *E. coli* O157:H7 isolates collected from NCBI to provide insight in the chromosomal homology, plasmids, resistance genes, virulence genes, genomic islands and prophages that are present. Our study demonstrated that although the *E. coli* O157:H7 strains belong to the same serotype group, mobile genetic elements can be transferred via horizontal gene resulting in differences between strains. Commensal strains can become pathogenic because the genetics in parts of their genome may code for virulent factor [10, 34]. STEC strains are able to adapt to multiple host conditions which provides these pathogens with the potential to expand their genomes [86]. Insight into the interactions between STEC strains and host cells will provide information on structural and functional features that result in the variation of STEC strains [2, 86]. This can be achieved by experimental confirmation to determine the evolving pathogenicity of *E. coli* O157:H7 strains which will shed light on developing strategies to detect and control the transmission of STEC in communities.

Methods

National Center for Biotechnology Information (NCBI) database

Reference strain sequence and all query strain sequences were selected from NCBI. In NCBI, *E. coli*, O157:H7 was searched. In the advance search all laboratory strains were excluded and only complete genomes were used. The list of strains used in this study is in Additional file 1

BLAST Ring Image Generator (BRIG) used to construct circular chromosomal maps

Chromosomal maps were created to compare a reference bacterial strain to all query bacterial strains using BLAST Ring Image Generator (BRIG) [48] BRIG uses BLAST

alignment to construct circular maps [87]. The annotated chromosome of *E. coli* O157:H7 Sakai was used as a reference for generating whole chromosomal sequence comparisons with query sequences. All default setting were used in BRIG.

Plasmid identification

PlasmidFinder (<https://cge.cbs.dtu.dk/services/PlasmidFinder/>) database was used to identify the presence of plasmids in the O157:H7 strains [88, 89]. All sequences of interest were combined into one file and uploaded in the program. There are four different selection options: select database, select threshold for minimum % identity, select minimum % coverage and select you read types. Default settings were used for select threshold for minimum % identity and select minimum % coverage, 95 and 60%, respectively. Enterobacteriales was selected as database and assembled or draft genome/contigs for read type.

Resistance identification

ResFinder (<https://cge.cbs.dtu.dk/services/ResFinder/>) database was used for the identification of resistant genes [89–91]. All sequences of interest were combined into one file and uploaded in the program. There are four different selection options: chromosomal point mutations, acquired antimicrobial resistance genes, select species and select you read types. Chromosomal point mutations and acquired antimicrobial resistance were selected. *E. coli* was selected as species and assembled or draft genome/contigs for read type.

Virulent gene identification

VirulenceFinder (<https://cge.cbs.dtu.dk/services/VirulenceFinder/>) database was used for the identification of virulence genes [89, 92, 93]. All sequences of interest were combined into one file and uploaded in the program. There are four different selection options: select species, select threshold for % ID, select minimum length and select you read types. Default settings were used for select threshold for % ID and select minimum length, 90 and 60%, respectively. *E. coli* was selected as species and assembled or draft genome/contigs for read type.

Genomic islands

Genomic islands (GIs) were first identified using IslandViewer 4 (<https://www.pathogenomics.sfu.ca/islandviewer/browse/>) [94] with the genome of *E. coli* Sakai strain as a reference. A GI was called when a prediction was made by at least one of the three methods (IslandPath-DIMOB, SIGI-HMM, and IslandPick).

PHASTER

The presence of prophages in the chromosome of all strains were determined by downloading each FASTA

file of the whole chromosomal sequence of this strain from NCBI followed by uploading the file to PHASTER [95, 96]. Prophages were identified into three groups: intact, questionable and incomplete based on the scores, a score that is > 90, a score that is 70–90) and a score that is < 70, respectively.

Abbreviations

BRIG	BLAST Ring Image Generator
<i>E. coli</i>	<i>Escherichia coli</i>
GC	guanine-cytosine content
GIs	Genomic islands
LEE	Locus of Enterocyte Effacement
NCBI	National Center for Biotechnology Information
Stx	Shiga toxin
STEC	Shiga toxin-producing <i>Escherichia coli</i>

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12864-023-09902-4>.

Additional file 1: Table S1. Strain name and corresponding accession number.

Additional file 2: Table S2: The presence of prophages in *Escherichia coli* O157:H7 strains.

Acknowledgements

Not applicable.

Authors' contributions

NN obtained, analyzed and interpreted all data for the present study. NN wrote the manuscript. All authors read and approved the final manuscript.

Authors' information

Not applicable.

Funding

This work was supported by the National Research Foundation [grant number 131156].

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Received: 20 March 2023 Accepted: 13 December 2023

Published online: 20 December 2023

References

- Smith JL, Fratamico PM, Gunther NW IV. Shiga toxin-producing *Escherichia coli*. *Adv Appl Microbiol*. 2014;86:145–97.

- Jiang L, Yang W, Jiang X, Yao T, Wang L, Yang B. Virulence-related O islands in enterohemorrhagic *Escherichia coli* O157:H7. *Gut Microbes*. 2021;13(1):1992237.
- Nataro JP, Kaper JB. Diarrheagenic *Escherichia coli*. *Clin Microbiol Rev*. 1998;11(1):142–201.
- Croxen MA, Law RJ, Scholz R, Keeney KM, Wlodarska M, Finlay BB. Recent advances in understanding enteric pathogenic *Escherichia coli*. *Clin Microbiol Rev*. 2013;26(4):822–80.
- Heiman KE, Mody RK, Johnson SD, Griffin PM, Gould LH. *Escherichia coli* O157 outbreaks in the United States, 2003–2012. *Emerg Infect Dis*. 2015;21(8):1293.
- White A, Cronquist A, Bedrick EJ, Scallan E. Food source prediction of Shiga toxin-producing *Escherichia coli* outbreaks using demographic and outbreak characteristics, United States, 1998–2014. *Foodborne Pathog Dis*. 2016;13(10):527–34.
- Steyert SR, Sahl JW, Fraser CM, Teel LD, Scheutz F, Rasko DA. Comparative genomics and stx phage characterization of LEE-negative Shiga toxin-producing *Escherichia coli*. *Front Cell Infect Microbiol*. 2012;2:133.
- Laing CR, Zhang Y, Gilmour MW, Allen V, Johnson R, Thomas JE, et al. A comparison of Shiga-toxin 2 bacteriophage from classical enterohemorrhagic *Escherichia coli* serotypes and the German E. Coli O104: H4 outbreak strain. *PLoS One*. 2012;7(5):e37362.
- Smith DL, Rooks DJ, Fogg PC, Darby AC, Thomson NR, McCarthy AJ, et al. Comparative genomics of Shiga toxin encoding bacteriophages. *BMC Genomics*. 2012;13(1):1–10.
- Nyholm O, Halkilahti J, Wiklund G, Okeke U, Paulin L, Auvinen P, et al. Comparative genomics and characterization of hybrid Shigatoxigenic and enterotoxigenic *Escherichia coli* (STEC/EPEC) strains. *PLoS One*. 2015;10(8):e0135936.
- Melton-Celsa AR. Shiga toxin (Stx) classification, structure, and function. *Microbiol Spectr*. 2014;2(4):2–4.
- Scheutz F, Teel LD, Beutin L, Piérard D, Buvens G, Karch H, et al. Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature. *J Clin Microbiol*. 2012;50(9):2951–63.
- Krüger A, Lucchesi PM. Shiga toxins and stx phages: highly diverse entities. *Microbiology*. 2015;161(3):451–62.
- Müller D, Greune L, Heusipp G, Karch H, Fruth A, Tschäpe H, et al. Identification of unconventional intestinal pathogenic *Escherichia coli* isolates expressing intermediate virulence factor profiles by using a novel single-step multiplex PCR. *Appl Environ Microbiol*. 2007;73(10):3380–90.
- Haugum K, Johansen J, Gabrielsen C, Brandal LT, Bergh K, Ussery DW, et al. Comparative genomics to delineate pathogenic potential in non-O157 Shiga toxin-producing *Escherichia coli* (STEC) from patients with and without haemolytic uremic syndrome (HUS) in Norway. *PLoS One*. 2014;9(10):e111788.
- Kurioka T, Yunou Y, Harada H, Kita E. Efficacy of antibiotic therapy for infection with Shiga-like toxin-producing *Escherichia coli* O157:H7 in mice with protein-calorie malnutrition. *Eur J Clin Microbiol Infect Dis*. 1999;18(8):561–71.
- Panos G, Betsi G, Falagas M. Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with *Escherichia coli* O157:H7 infection? *Aliment Pharmacol Ther*. 2006;24(5):731–42.
- McGannon CM, Fuller CA, Weiss AA. Different classes of antibiotics differentially influence Shiga toxin production. *Antimicrob Agents Chemother*. 2010;54(9):3790–8.
- Knobloch J, Hauswaldt S, Solbach W, Nitschke M, Sayk F. Antibiotic therapy in Shiga toxin producing *Escherichia coli* infection and colonization. *GMS Infect Dis*. 2013;1:7.
- Tajiri H, Nishi J, Ushijima K, Shimizu T, Ishige T, Shimizu M, et al. A role for fosfomycin treatment in children for prevention of haemolytic-uraemic syndrome accompanying Shiga toxin-producing *Escherichia coli* infection. *Int J Antimicrob Agents*. 2015;46(5):586–9.
- Mir RA, Kudva IT. Antibiotic-resistant Shiga toxin-producing *Escherichia coli*: an overview of prevalence and intervention strategies. *Zoonoses Public Health*. 2019;66(1):1–13.
- Garcia PG, Silva VL, Diniz CG. Occurrence and antimicrobial drug susceptibility patterns of commensal and diarrheagenic *Escherichia coli* in fecal microbiota from children with and without acute diarrhea. *J Microbiol*. 2011;49(1):46–52.
- Mahanti A, Samanta I, Bandopadhyay S, Joardar S, Dutta T, Batabyal S, et al. Isolation, molecular characterization and antibiotic resistance of

- Shiga toxin-producing *Escherichia coli* (STEC) from buffalo in India. *Lett Appl Microbiol.* 2013;56(4):291–8.
24. Ahmed AM, Shimamoto T. Molecular analysis of multidrug resistance in Shiga toxin-producing *Escherichia coli* O157: H7 isolated from meat and dairy products. *Int J Food Microbiol.* 2015;193:68–73.
 25. Amézquita-López BA, Quiñones B, Soto-Beltrán M, Lee BG, Yambao JC, Lugo-Melchor OY, et al. Antimicrobial resistance profiles of Shiga toxin-producing *Escherichia coli* O157 and non-O157 recovered from domestic farm animals in rural communities in northwestern Mexico. *Antimicrob Resist Infect Control.* 2016;5(1):1–6.
 26. Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ. Molecular mechanisms of antibiotic resistance. *Nat Rev Microbiol.* 2015;13(1):42–51.
 27. Von Wintersdorff CJ, Penders J, Van Niekerk JM, Mills ND, Majumder S, Van Alphen LB, et al. Dissemination of antimicrobial resistance in microbial ecosystems through horizontal gene transfer. *Front Microbiol.* 2016;7:173.
 28. Fluit A, Schmitz F. Class 1 integrons, gene cassettes, mobility, and epidemiology. *Eur J Clin Microbiol Infect Dis.* 1999;18(11):761–70.
 29. Losada L, DebRoy C, Radune D, Kim M, Sanka R, Brinkac L, et al. Whole genome sequencing of diverse Shiga toxin-producing and non-producing *Escherichia coli* strains reveals a variety of virulence and novel antibiotic resistance plasmids. *Plasmid.* 2016;83:8–11.
 30. Schroeder CM, Zhao C, DebRoy C, Torcolini J, Zhao S, White DG, et al. Antimicrobial resistance of *Escherichia coli* O157 isolated from humans, cattle, swine, and food. *Appl Environ Microbiol.* 2002;68(2):576–81.
 31. Fratamico PM, Yan X, Caprioli A, Esposito G, Needleman DS, Pepe T, et al. The complete DNA sequence and analysis of the virulence plasmid and of five additional plasmids carried by Shiga toxin-producing *Escherichia coli* O26: H11 strain H30. *Int J Med Microbiol.* 2011;301(3):192–203.
 32. Lawrence JG, Ochman H. Molecular archaeology of the *Escherichia coli* genome. *Proc Natl Acad Sci.* 1998;95(16):9413–7.
 33. Hayashi T, Makino K, Ohnishi M, Kurokawa K, Ishii K, Yokoyama K, et al. Complete genome sequence of enterohemorrhagic *Escherichia coli* O157: H7 and genomic comparison with a laboratory strain K-12. *DNA Res.* 2001;8(1):11–22.
 34. Rasko DA, Rosovitz M, Myers GS, Mongodin EF, Fricke WF, Gajer P, et al. The pangenome structure of *Escherichia coli*: comparative genomic analysis of *E. coli* commensal and pathogenic isolates. *J Bacteriol.* 2008;190(20):6881–93.
 35. Lukjancenko O, Wassenaar TM, Ussery DW. Comparison of 61 sequenced *Escherichia coli* genomes. *Microb Ecol.* 2010;60(4):708–20.
 36. Rohde H, Qin J, Cui Y, Li D, Loman NJ, Hentschke M, et al. Open-source genomic analysis of Shiga-toxin-producing *E. coli* O104: H4. *N Engl J Med.* 2011;365(8):718–24.
 37. Hazen TH, Sahl JW, Fraser CM, Donnenberg MS, Scheutz F, Rasko DA. Refining the pathovar paradigm via phylogenomics of the attaching and effacing *Escherichia coli*. *Proc Natl Acad Sci.* 2013;110(31):12810–5.
 38. Riley LW, Remis RS, Helgason SD, McGee HB, Wells JG, Davis BR, et al. Hemorrhagic colitis associated with a rare *Escherichia coli* serotype. *N Engl J Med.* 1983;308(12):681–5.
 39. Zhang Y, Laing C, Steele M, Ziebell K, Johnson R, Benson AK, et al. Genome evolution in major *Escherichia coli* O157: H7 lineages. *BMC Genomics.* 2007;8(1):1–16.
 40. Manning SD, Motiwala AS, Springman AC, Qi W, Lacher DW, Ouellette LM, et al. Variation in virulence among clades of *Escherichia coli* O157: H7 associated with disease outbreaks. *Proc Natl Acad Sci.* 2008;105(12):4868–73.
 41. Ogura Y, Ooka T, Iguchi A, Toh H, Asadulghani M, Oshima K, et al. Comparative genomics reveal the mechanism of the parallel evolution of O157 and non-O157 enterohemorrhagic *Escherichia coli*. *Proc Natl Acad Sci.* 2009;106(42):17939–44.
 42. Eppinger M, Mammel MK, LeClerc JE, Ravel J, Cebula TA. Genome signatures of *Escherichia coli* O157: H7 isolates from the bovine host reservoir. *Appl Environ Microbiol.* 2011;77(9):2916–25.
 43. Majowicz SE, Scallan E, Jones-Bitton A, Sargeant JM, Stapleton J, Angulo FJ, et al. Global incidence of human Shiga toxin-producing *Escherichia coli* infections and deaths: a systematic review and knowledge synthesis. *Foodborne Pathog Dis.* 2014;11(6):447–55.
 44. Carter MQ, Parker CT, Louie JW, Huynh S, Fagerquist CK, Mandrell RE. *RcsB* contributes to the distinct stress fitness among *Escherichia coli* O157: H7 curl variants of the 1993 hamburger-associated outbreak strains. *Appl Environ Microbiol.* 2012;78(21):7706–19.
 45. Sharma V, Bayles D, Alt D, Looft T, Brunelle B, Stasko J. Disruption of *rcsB* by a duplicated sequence in a curl-producing *Escherichia coli* O157: H7 results in differential gene expression in relation to biofilm formation, stress responses and metabolism. *BMC Microbiol.* 2017;17(1):1–23.
 46. Uhlich GA, Chen C-Y, Cottrell BJ, Hofmann CS, Dudley EG, Strobaugh TP Jr, et al. Phage insertion in *mlrA* and variations in *rpoS* limit curl expression and biofilm formation in *Escherichia coli* serotype O157: H7. *Microbiol-ogy.* 2013;159(Pt_8):1586–96.
 47. Carter MQ, Louie JW, Huynh S, Parker CT. Natural *rpoS* mutations contribute to population heterogeneity in *Escherichia coli* O157: H7 strains linked to the 2006 US spinach-associated outbreak. *Food Microbiol.* 2014;44:108–18.
 48. Sharma VK, Akavaram S, Schaut RG, Bayles DO. Comparative genomics reveals structural and functional features specific to the genome of a foodborne *Escherichia coli* O157: H7. *BMC Genomics.* 2019;20(1):1–18.
 49. Ohnishi M, Kurokawa K, Hayashi T. Diversification of *Escherichia coli* genomes: are bacteriophages the major contributors? *Trends Microbiol.* 2001;9(10):481–5.
 50. Perna NT, Plunkett G, Burland V, Mau B, Glasner JD, Rose DJ, et al. Genome sequence of enterohaemorrhagic *Escherichia coli* O157: H7. *Nature.* 2001;409(6819):529–33.
 51. Miryala SK, Ramaiah S. Exploring the multi-drug resistance in *Escherichia coli* O157: H7 by gene interaction network: a systems biology approach. *Genomics.* 2019;111(4):958–65.
 52. Paramita RI, Nelwan EJ, Fadilah F, Renesteen E, Puspendari N, Erlina L. Genome-based characterization of *Escherichia coli* causing bloodstream infection through next-generation sequencing. *PLoS One.* 2020;15(12):e0244358.
 53. Edgar R, Bibi E. MdfA, an *Escherichia coli* multidrug resistance protein with an extraordinarily broad spectrum of drug recognition. *J Bacteriol.* 1997;179(7):2274–80.
 54. Rijavec M, Erjavec MS, Avguštin JA, Reissbrodt R, Fruth A, Križan-Hergouth V, et al. High prevalence of multidrug resistance and random distribution of mobile genetic elements among uropathogenic *Escherichia coli* (UPEC) of the four major phylogenetic groups. *Curr Microbiol.* 2006;53(2):158–62.
 55. Munita JM, Arias CA. Mechanisms of antibiotic resistance. *Microbio Spectr.* 2016;4(2):4.2.15.
 56. Meek RW, Vyas H, Piddock LJV. Nonmedical uses of antibiotics: time to restrict their use? *PLoS Biol.* 2015;13(10):e1002266.
 57. Alonso C, Zarazaga M, Ben Sallem R, Jouini A, Ben Slama K, Torres C. Antibiotic resistance in *Escherichia coli* in husbandry animals: the African perspective. *Lett Appl Microbiol.* 2017;64(5):318–34.
 58. Boyd DA, Tyler S, Christianson S, McGeer A, Muller MP, Willey BM, et al. Complete nucleotide sequencing of a 92-kilobase plasmid harboring the CTX-M-15 extended-spectrum beta-lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada. *Antimicrob Agents Chemother.* 2004;48(10):3758–64.
 59. Yang Q-E, Sun J, Li L, Deng H, Liu B-T, Fang L-X, et al. *IncF* plasmid diversity in multi-drug resistant *Escherichia coli* strains from animals in China. *Front Microbiol.* 2015;6:964.
 60. Villa L, García-Fernández A, Fortini D, Carattoli A. Replicon sequence typing of *IncF* plasmids carrying virulence and resistance determinants. *J Antimicrob Chemother.* 2010;65(12):2518–29.
 61. Johnson TJ, Nolan LK. Pathogenomics of the virulence plasmids of *Escherichia coli*. *Microbiol Mol Biol Rev.* 2009;73(4):750–74.
 62. Lambrecht E, Van Meerveen E, Boon N, Van de Wiele T, Wattiau P, Herman L, et al. Characterization of cefotaxime- and ciprofloxacin-resistant commensal *Escherichia coli* originating from Belgian farm animals indicates high antibiotic resistance transfer rates. *Microb Drug Resist.* 2018;24(6):707–17.
 63. Mshana SE, Imirzalioglu C, Hossain H, Hain T, Domann E, Chakraborty T. Conjugative *IncFI* plasmids carrying CTX-M-15 among *Escherichia coli* ESBL producing isolates at a university hospital in Germany. *BMC Infect Dis.* 2009;9(1):1–8.
 64. Boyd EF, Hill CW, Rich SM, Hartl DL. Mosaic structure of plasmids from natural populations of *Escherichia coli*. *Genetics.* 1996;143(3):1091–100.
 65. Noll LW, Worley JN, Yang X, Shridhar PB, Ludwig JB, Shi X, et al. Comparative genomics reveals differences in mobile virulence genes of *Escherichia coli* O103 pathotypes of bovine fecal origin. *PLoS One.* 2018;13(2):e0191362.

66. Zhang P, Essendoubi S, Keenlside J, Reuter T, Stanford K, King R, et al. Genomic analysis of Shiga toxin-producing *Escherichia coli* O157: H7 from cattle and pork-production related environments. *npj Sci Food*. 2021;5(1):1–12.
67. Liu B-T, Yang Q-E, Li L, Sun J, Liao X-P, Fang L-X, et al. Dissemination and characterization of plasmids carrying *oqxAB-Bla CTX-M* genes in *Escherichia coli* isolates from food-producing animals. *PLoS One*. 2013;8(9):e73947.
68. Liao X-P, Liu B-T, Yang Q-E, Sun J, Li L, Fang L-X, et al. Comparison of plasmids coharboring 16S rRNA methylase and extended-spectrum β -lactamase genes among *Escherichia coli* isolates from pets and poultry. *J Food Prot*. 2013;76(12):2018–23.
69. Petersen L, Bollback JP, Dimmic M, Hubisz M, Nielsen R. Genes under positive selection in *Escherichia coli*. *Genome Res*. 2007;17(9):1336–43.
70. Garmendia J, Phillips AD, Carlier MF, Chong Y, Schüller S, Marches O, et al. TccP is an enterohaemorrhagic *Escherichia coli* O157: H7 type III effector protein that couples Tir to the actin-cytoskeleton. *Cell Microbiol*. 2004;6(12):1167–83.
71. Gonzalez-Escalona N, Allard MA, Brown EW, Sharma S, Hoffmann M. Nanopore sequencing for fast determination of plasmids, phages, virulence markers, and antimicrobial resistance genes in Shiga toxin-producing *Escherichia coli*. *PLoS One*. 2019;14(7):e0220494.
72. Knutton S, Baldwin T, Williams P, McNeish A. Actin accumulation at sites of bacterial adhesion to tissue culture cells: basis of a new diagnostic test for enteropathogenic and enterohemorrhagic *Escherichia coli*. *Infect Immun*. 1989;57(4):1290–8.
73. Boerlin P, McEwen SA, Boerlin-Petzold F, Wilson JB, Johnson RP, Gyles CL. Associations between virulence factors of Shiga toxin-producing *Escherichia coli* and disease in humans. *J Clin Microbiol*. 1999;37(3):497–503.
74. Ostroff SM, Tarr PI, Neill MA, Lewis JH, Hargrett-Bean N, Kobayashi JM. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in *Escherichia coli* O157: H7 infections. *J Infect Dis*. 1989;160(6):994–8.
75. Iwu CD, du Plessis E, Korsten L, Okoh AI. Prevalence of *E. Coli* O157: H7 strains in irrigation water and agricultural soil in two district municipalities in South Africa. *Int J Environ Stud*. 2021;78(3):474–83.
76. Schmidt H, Scheef J, Huppertz H, Frosch M, Karch H. *Escherichia coli* O157: H7 and O157: H– strains that do not produce Shiga toxin: phenotypic and genetic characterization of isolates associated with diarrhea and hemolytic-uremic syndrome. *J Clin Microbiol*. 1999;37(11):3491–6.
77. Karch H, Schubert S, Zhang D, Zhang W, Schmidt H, Olschlager T, et al. A genomic island, termed high-pathogenicity island, is present in certain non-O157 Shiga toxin-producing *Escherichia coli* clonal lineages. *Infect Immun*. 1999;67(11):5994–6001.
78. Hacker J, Kaper JB. The concept of pathogenicity islands. Pathogenicity islands and other mobile virulence elements 1999:1–11.
79. Teng L, Lee S, Park D, Jeong KC. Genetic and functional analyses of virulence potential of an *Escherichia coli* O157: H7 strain isolated from super-shedder cattle. *Front Cell Infect Microbiol*. 2020;10:271.
80. Bobay L-M, Rocha EP, Touchon M. The adaptation of temperate bacteriophages to their host genomes. *Mol Biol Evol*. 2013;30(4):737–51.
81. Delannoy S, Mariani-Kurkdjian P, Webb HE, Bonacorsi S, Fach P. The mobilome; a major contributor to *Escherichia coli* stx2-positive O26: H11 strains intra-serotype diversity. *Front Microbiol*. 2017;8:1625.
82. Weinroth MD, Clawson ML, Arthur TM, Wells JE, Brichta-Harhay DM, Strachan N, et al. Rates of evolutionary change of resident *Escherichia coli* O157: H7 differ within the same ecological niche. *BMC Genomics*. 2022;23(1):1–15.
83. Yan X, Fratamico PM, Bono JL, Baranzoni GM, Chen C-Y. Genome sequencing and comparative genomics provides insights on the evolutionary dynamics and pathogenic potential of different H-serotypes of Shiga toxin-producing *Escherichia coli* O104. *BMC Microbiol*. 2015;15(1):1–20.
84. Cooper KK, Mandrell RE, Louie JW, Korlach J, Clark TA, Parker CT, et al. Comparative genomics of enterohemorrhagic *Escherichia coli* O145: H28 demonstrates a common evolutionary lineage with *Escherichia coli* O157: H7. *BMC Genomics*. 2014;15(1):1–17.
85. Katani R, Cote R, Kudva IT, DebRoy C, Arthur TM, Kapur V. Comparative genomics of two super-shedder isolates of *Escherichia coli* O157: H7. *PLoS One*. 2017;12(8):e0182940.
86. Carter MQ, Laniohan N, Lo C-C, Chain PS. Comparative genomics applied to systematically assess pathogenicity potential in Shiga toxin-producing *Escherichia coli* O145: H28. *Microorganisms*. 2022;10(5):866.
87. Alikhan N-F, Petty NK, Ben Zakour NL, Beatson SA. BLAST ring image generator (BRIG): simple prokaryote genome comparisons. *BMC Genomics*. 2011;12(1):1–10.
88. Carattoli A, Zankari E, Garcia-Fernandez A, Larsen MV, Lund O, Villa L, et al. PlasmidFinder and pMLST: in silico detection and typing of plasmids. *Antimicrob Agents Chemother*. 2014;AAC. 02412-14.
89. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, et al. BLAST+: architecture and applications. *BMC Bioinformatics*. 2009;10:1–9.
90. Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, et al. ResFinder 4.0 for predictions of phenotypes from genotypes. *J Antimicrob Chemother*. 2020;75(12):3491–500.
91. Zankari E, Allesøe R, Joensen KG, Cavaco LM, Lund O, Aarestrup FM. PointFinder: a novel web tool for WGS-based detection of antimicrobial resistance associated with chromosomal point mutations in bacterial pathogens. *J Antimicrob Chemother*. 2017;72(10):2764–8.
92. Joensen KG, Scheutz F, Lund O, Hasman H, Kaas RS, Nielsen EM, et al. Real-time whole-genome sequencing for routine typing, surveillance, and outbreak detection of verotoxigenic *Escherichia coli*. *J Clin Microbiol*. 2014;52(5):1501–10.
93. Malberg Tetzschner AM, Johnson JR, Johnston BD, Lund O, Scheutz F. In silico genotyping of *Escherichia coli* isolates for extraintestinal virulence genes by use of whole-genome sequencing data. *J Clin Microbiol*. 2020;58(10):e01269–20.
94. Bertelli C, Laird MR, Williams KP, Group SFURC, Lau BY, Hoad G, et al. IslandViewer 4: expanded prediction of genomic islands for larger-scale datasets. *Nucleic Acids Res*. 2017;45(W1):W30–W5.
95. Zhou Y, Liang Y, Lynch KH, Dennis JJ, Wishart DS. PHAST: a fast phage search tool. *Nucleic Acids Res*. 2011;39(suppl_2):W347–W52.
96. Arndt D, Grant JR, Marcu A, Sajed T, Pon A, Liang Y, et al. PHASTER: a better, faster version of the PHAST phage search tool. *Nucleic Acids Res*. 2016;44(W1):W16–21.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.